Effects of ceiling fan use on cardiovascular autonomic function during simulated indoor overheating in bed-resting older adults.

Exp PhysiolSep 3, 2026 (epub)
Clinical ResearchGeriatricsCardiologyOpen access

Fergus K O'Connor, Robert D Meade, Kristina-Marie T Janetos et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized crossover trial investigated the effects of ceiling fan use on cardiovascular autonomic function in 20 healthy older adults during simulated indoor overheating. Results showed that ceiling fan use reduced peak core temperature by 0.2°C and heart rate by 5 beats/min, while partially preserving RMSSD. However, it did not significantly affect other cardiovascular measures.

Key findings

  • Ceiling fan use reduced peak core temperature by 0.2°C (95% CI: 0.1-0.3; P < 0.001).
  • Heart rate decreased by 5 beats/min (P = 0.03) with fan use.
  • RMSSD was preserved by 4.7 ms (P = 0.04) during fan use.

Why it matters

Understanding the impact of cooling interventions like ceiling fans on cardiovascular function is crucial for managing heat-related risks in older adults, who are particularly vulnerable to heat stress and its complications.

Source

PubMed · PMID 42693775Free full text on PubMed Central

Published in Exp Physiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.